Amneal Pharmaceuticals (AMRX) Non-Current Debt (2017 - 2026)

Amneal Pharmaceuticals has reported Non-Current Debt for 10 years, with the latest figure at $2.6 billion in Q2 2026.

• On a quarterly basis, Non-Current Debt rose 18.03% year-over-year to $2.6 billion in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 18.03% increase from a year earlier, with the FY2025 full-year figure at $2.6 billion, up 7.79% from the prior year.
• Non-Current Debt was $2.6 billion for Q2 2026 at Amneal Pharmaceuticals, roughly flat from $2.6 billion in the prior quarter.
• The five-year high for Non-Current Debt was $2.7 billion in Q1 2022, with the low at $2.2 billion in Q2 2025.
• Average Non-Current Debt over 5 years is $2.5 billion, with a median of $2.6 billion recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Non-Current Debt slipped 9.37% in 2025, then increased 18.03% in 2026.
• Over 5 years, Non-Current Debt stood at $2.6 billion in 2022, then declined by 7.7% to $2.4 billion in 2023, then decreased by 1.41% to $2.4 billion in 2024, then gained by 7.79% to $2.6 billion in 2025, then slipped by 0.06% to $2.6 billion in 2026.
• The last three Non-Current Debt figures came in at $2.6 billion (Q2 2026), $2.6 billion (Q1 2026), and $2.6 billion (Q4 2025), per Business Quant data.